Penumbra Inc. (PEN)
NYSE: PEN · Surgical & Medical Instruments & Apparatus · Alameda, CA
Our rating: Neutral
Neutral reaffirmed at $318.95, moderate conviction, October 30, 2026.
Breaks if: The Neutral call turns Positive if Penumbra reports revenue growth above 20% alongside net margin expansion above 15% for two consecutive quarters — evidence the company is growing into rather than merely sustaining its multiple. It turns Cautious if revenue growth decelerates below 10% in any single reported quarter, or net margin falls below 10% for two consecutive quarters, signaling that the embedded growth assumption is breaking rather than being met.
Key figures
| Market value | $12.6B |
|---|---|
| Revenue, last 12 months | $1.6B |
| Net income, last 12 months | $157M |
| Free cash flow, last 12 months | $200M |
| Price to earnings | 80.1× |
| Free cash flow yield | 1.6% |
| Dividend yield | 0.0% |
| Operating margin | 12.1% |
| Return on equity | 10.7% |
| Beta to the S&P 500 | 0.46 |
| Volatility, annualized | 33.3% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $410M | 15.6% | $1.07 | $26M |
| June 30, 2026 | $390M | 14.9% | $0.88 | $33M |
| March 31, 2026 | $375M | 15.6% | $0.82 | $73M |
| December 31, 2025 | $385M | 22.1% | $1.20 | $68M |
| September 30, 2025 | $355M | 17.8% | $1.17 | $42M |
| June 30, 2025 | $339M | 13.4% | $1.15 | $29M |
| March 31, 2025 | $324M | 16.3% | $1.00 | $36M |
| December 31, 2024 | $316M | 10.8% | $0.87 | $46M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.45B: Claude 52%, Gemini 90%, Mistral 55%
- Diluted earnings per share are at least $1.20: Claude 45%, Gemini 25%, Mistral 30%
- Free cash flow for the quarter is at least $0.07B: Claude 45%, Gemini 85%, Mistral 55%
8 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.